Replies to post #65846 on Biotech Values

[iwfal]

I don't think one needs the dev-stage biotech to do the diversifying for one.

I would suggest you have missed my point. None of my listed benefits to a company having a big pipeline were about risk diversification. That was no accident. It was that there are substantial other benefits to having a big pipeline - behavioral changes, ... .

It was always the least impressive of their products in terms of upside. Now it is not helping them generate cash to fund the interesting stuff, and indeed appears to have cost them the chunk of atacicept that they gave up.

Agree it was always the least impressive. It was just the safest. And it is ramping up on the slow end of what I expected - but I still think that it will be cash flow positive before the end of the year (as a stand alone entity). And will hit $35M per q by Q1. Unless Bayer was willing to fork over, say, $300M now and 20% royalties going forward I wouldn't give it up.

so they can get on with i lambda and IL 21

I think IL-31 ab looks more promising that IL-21, FWIW. Even in a very quick glance.